SUPPLEMENTARY INFORMATION

**Supplementary Figure S1. Pharmacodynamic analyses of LINE1 and specific gene demethylation.** A: Change in CpG site methylation of LINE-1 in PBMCs from subjects in the G+C arm (n= 49). B: Average change in CpG site methylation of LINE-1 in PBMCs from subjects in the G+C arm with at least two treatment cycles and best clinical response (n= 15). Patients with or without increased LINE-1 demethylation after cycle 1 of G+C treatment are shown on the left and right, respectively. C: Gene-specific demethylation in paired tumor biopsies from subjects in the G+C arm (n=8). BRCA1 was measured, but is not shown due to extremely low signal and no significant changes observed. Error bars represent standard error of the mean. n=number of cycles for each subject; PR=partial response; SD=stable disease.



Supplementary Table S1. Genes tested for promoter methylation in tumor biopsies

|  |
| --- |
| Genes for methylation analysis |
|  |
| MAGEA2 |
| MAGEA3 |
| MAGEA11 |
| RASSF1A |
| NY-ESO-1 |
| MLH1 |
| BRCA1 |
| HOXA11 |

**Supplementary Table S2. Summary of CA-125 reduction#**

|  | **G+C**a**(n=51)** | **TC****(n=49)** | **Crossover****TC to G+C**a**(n=27)** |
| --- | --- | --- | --- |
| **Patients with Best Post-baseline CA-125 Percent Reduction ≥ 50%** |  |  |  |  |  |  |
|  n (%) | 15 | (36)b | 13 | (32)b | 6  | (29)b |
|  (95% CI) | (21.6, 52.0) | (18.1, 48.1) | (11.3, 52.2) |
|  |  |  |  |  |  |  |
| **Best (Most Reduced) Percent Change From Baseline** |  |  |  |
|  n | 42 | 41 | 21 |
|  Mean  | -25.02 | -5.06 | -22.45 |
|  SD | 63.58 | 74.63 | 40.18 |
|  SE | 9.81 | 11.66 | 8.77 |
|  Median | -43.16 | -10.15 | -32.16 |
|  Min | -97.6 | -98.3 | -97.3 |
|  Max | 153.8 | 247.8 | 53.0 |
| # Assessed in all patients who had a CA125 > 70 or 2XULN (includes both patients with detectable and measurable disease)aGuadecitabine 30 mg/m2 on Days 1-5 and carboplatin AUC 4 on Day 8 of 28-day treatment cycles.bPercentages are based on a denominator of 42, 41, and 21 subjects in the G+C, TC, and TC crossover groups, respectively who had a CA125 > 70 or 2X ULN. |

**Supplementary Table S3: Patient disposition and reason for subject discontinuation of trial treatment**

|  |  |  |  |
| --- | --- | --- | --- |
| **Patient Disposition** | **G+C**a**(n=51)** | **TC****(n=49)** | **Crossover****TC to G+C**a**(n=27)** |
| Patients Enrolled/Randomized/Treatedb | 51 |  | 49 |  | 27 |  |
| Patients treated (Safety data set) | 51 | (100) | 49 | (100) | 27 | (100) |
| Efficacy analysis data set | 51 | (100) | 49 | (100) | 27 | (100) |
| Reason for treatment discontinuation |  |  |  |  |  |  |
| Disease progression | 41 | (80) | 39 | (80) | 21 | (78) |
| AE | 3 | (6) | 3 | (6) | 2 | (7) |
| Patient decision | 2 | (4) | 2 | (4) | 0 |  |
| Investigator discretion | 3 | (6) | 2 | (4) | 2 | (7) |
| Other | 2 | (4) | 3 | (6) | 2 | (7) |
| Trial discontinuation |  |  |  |  |  |  |
| Withdrawal of consent | 1 | (2) | 2 | (4) | 0 |  |
| Death | 43 | (84) | 18 | (37) | 22 | (81) |
| Lost to follow-up | 0 |  | 0 |  | 1 | (4) |
| Database lock | 7 | (14) | 2 | (4) | 4 | (15) |
| aGuadecitabine 30 mg/m2 on Days 1-5 and carboplatin AUC 4 on Day 8 of 28-day treatment cycles.bThree subjects (07-06 randomized to G+C, and 05-05 and 11-01 randomized to TC) were enrolled but not treated and are not included in the table. |